Eszopiclone
- Atc Codes:N05CF04
- CAS Codes:138729-47-2
- PHARMGKB ID:138729-47-2
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
North America
USA: Lunesta.
Latin America
Argentina: 8 Horas, Inductal, Miapax, Novo Insomnium.
Drug combinations
Chemistry
Eszopiclone: C~17~H~17~ClN~6~O~3~. Mw: 388.81. (1) 1-Piperazinecarboxylic acid, 4-methyl-, (5S)-6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester; (2)(+)-(5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate. CAS-138729-47-2 (2002).
Pharmacologic Category
Anxiolytics, Sedatives, and Hypnotics; Miscellaneous. Nonbenzodiazepine Hypnotic. (ATC-Code: N05CF04).
Mechanism of action
The S-enantiomer of zopiclone is a sedative, hypnotic agent structurally unrelated to benzodiazepines. May interact with GABA-receptor complexes at binding domains located close to or allosterically coupled to benzodiazepine receptors.
Therapeutic use
Used as a hypnotic agent in the management of transient and chronic insomnia.
Pregnancy and lactiation implications
No evidence of teratogenicity in animal models (high dose). There are no adequate, well-controlled studies in pregnant women. Use only if clearly needed. Use in nursing women not recommended.
Unlabeled use
Contraindications
None known to date.
Warnings and precautions
Abnormal thinking/behavioral changes may occur (aggression, agitation, bizarre behavior, decreased inhibition, hallucinations, and depersonalization). Amnesia can occur. May cause CNS depression. Use associated with hypersensitivity reactions including anaphylaxis and angioedema. Increased risk for hazardous sleep-related activities. Use with caution in depression, history of drug dependence, hepatic impairment, respiratory compromise, COPD or sleep apnea, and in the elderly. Use with caution in patients receiving other CNS depressants or psychoactive medication (effects may be potentiated), and in patients taking strong CYP3A4 inhibitors. Non-resolution of sleep disturbance after 7-10 days may indicate psychiatric and/or medical illness. Rapid onset of action. Abrupt discontinuance may lead to withdrawal symptoms.